RPL554

DRUG4 trials

Sponsors

Verona Pharma plc

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DisorderCystic FibrosisInflammatory Disorder of the Respiratory Tract

Phase 1

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

CompletedNCT02307162

Verona Pharma plcChronic Obstructive Pulmonary Disorder, Inflammatory Disorder of the Respiratory Tract

Start: 2014-12-31End: 2015-07-31Updated: 2015-10-28

Phase 2

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

CompletedNCT02427165

Verona Pharma plcAsthma

Start: 2015-04-30End: 2015-11-30Updated: 2016-09-09

The Effects of RPL554 on Top of Standard COPD Reliever Medications

CompletedNCT02542254

Verona Pharma plcChronic Obstructive Pulmonary Disease

Start: 2015-10-31End: 2015-12-31Updated: 2016-09-09

A Study of RPL554 in Patients With Cystic Fibrosis

CompletedNCT02919995

Verona Pharma plcCystic Fibrosis

Start: 2017-02-08End: 2017-11-03Updated: 2024-05-21

Related Papers

Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.

2019-06-1438 citations